Letters/Replies
Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius
Alfred Sandrock MD, PhD,
Corresponding Author
Alfred Sandrock MD, PhD
Research & Development, Biogen, Cambridge, MA, USA
Address correspondence to Dr Alfred Sandrock, Research & Development, Biogen, 225 Binney Street, Cambridge, MA 02142. E-mail: [email protected]
Search for more papers by this author
Alfred Sandrock MD, PhD,
Corresponding Author
Alfred Sandrock MD, PhD
Research & Development, Biogen, Cambridge, MA, USA
Address correspondence to Dr Alfred Sandrock, Research & Development, Biogen, 225 Binney Street, Cambridge, MA 02142. E-mail: [email protected]
Search for more papers by this author
First published: 23 October 2021
No abstract is available for this article.
References
- 1Moghavem N, Henderson VW, Greicius MD. Medicare should not cover aducanumab as a treatment for Alzheimer's disease. Ann Neurol 2021; 90: 331–333.
- 2 Aduhelm (aducanumab). Prescribing information. Cambridge, MA: Biogen, Inc, 2021.
- 3Salloway S, Cummings J. Aducanumab, amyloid lowering, and slowing of Alzheimer disease. Neurology 2021; 97: 543–544. https://doi.org/10.1212/WNL.0000000000012451.
- 4Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease—The FDA's perspective. JAMA Intern Med 2021; 181: 1276–1278. https://doi.org/10.1001/jamainternmed.2021.4607.
- 5Rentz DM, Wessels AM, Bain LJ, et al. Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable. Alzheimers Dement 2020; 16: 814.
- 6DiBenedetti DB, Slota C, Wronski S, et al. Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcome. Alzheimers Res Ther 2020; 12: 90.
- 7Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864–870.
- 8Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012; 488: 96–99.
- 9 Alzheimer's Association. 2021 Alzheimer's Disease Facts and Figures. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf. Accessed July 26, 2021
- 10Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–1122.
- 11Davis M, O'Connell T, Johnson S, et al. Estimating Alzheimer's disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res 2018; 15: 777–788.
